Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset
Ermium Therapeutics announced a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.
Advanced Medical Solutions Group plc announces its unaudited interim results for the six months ended 30 June 2019.
Amphion Innovations plc announces that 1,150,000 shares in Partner Company, Polarean Imaging plc have been sold for partial repayment of the loan facility originally announced on 5 June 2014 and most recently amended as announced on 1 April 2019.
InDevR, Inc. announced that it has raised a $7 million Series A round of equity financing from Adjuvant Capital.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
Proceeds to fund multi-centre study of STAR Mapping to improve outcomes of persistent Atrial Fibrillation treatment
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
Lightcast Discovery Ltd announces that it has raised £1.3 m in seed financing from private investors to develop the capabilities and applications of its platform including continuing to expand its range of pilot studies.
4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close